In the Appendix 4E and Annual Report some wording (page 14) seemed to allude to part of the revenue attributable to sales in Australia. "OncoSil had a cash balance of $12.2 million as at 30 June 2021. During the year, OncoSil made modest inaugural revenue from
the sale of the OncoSil™ device of $213k in Australia and New Zealand".
In the Appendix 4E and Annual Report some wording (page 14)...
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.76M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.5¢ | 1.4¢ | $97.02K | 6.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1730138 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 3600037 | 11 |
View Market Depth
| Last trade - 13.54pm 08/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |